Vertex Pharmaceuticals Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
6,100
- Stock Symbol
-
VRTX
- Investments
-
21
- Share Price
-
$489.10
- (As of Thursday Closing)
Vertex Pharmaceuticals General Information
Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact Information
Website
www.vrtx.comCorporate Office
- 50 Northern Avenue
- Boston, MA 02210
- United States
Corporate Office
- 50 Northern Avenue
- Boston, MA 02210
- United States
Vertex Pharmaceuticals Stock Performance
As of 17-Apr-2025, Vertex Pharmaceuticals’s stock price is $489.10. Its current market cap is $126B with 257M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $489.10 | $485.89 | $377.85 - $519.88 | $126B | 257M | 1.54M | -$2.08 |
Vertex Pharmaceuticals Financials Summary
As of 31-Dec-2024, Vertex Pharmaceuticals has a trailing 12-month revenue of $11B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 98,885,445 | 98,885,445 | 93,665,211 | 65,181,258 |
| Revenue | 11,020,100 | 11,020,100 | 9,869,200 | 8,930,700 |
| EBITDA | (111,800) | (111,800) | 3,990,500 | 4,290,900 |
| Net Income | (535,600) | (535,600) | 3,619,600 | 3,322,000 |
| Total Assets | 22,533,200 | 22,533,200 | 22,730,200 | 18,150,900 |
| Total Debt | 1,749,500 | 1,749,500 | 808,400 | 899,700 |
Vertex Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vertex Pharmaceuticals Comparisons
Industry
Financing
Details
Vertex Pharmaceuticals Competitors (45)
One of Vertex Pharmaceuticals’s 45 competitors is Regeneron Pharmaceuticals, a Formerly VC-backed company based in Tarrytown, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Bluebird Bio | Formerly VC-backed | Somerville, MA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Altimmune | Corporate Backed or Acquired | Gaithersburg, MD | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA |
Vertex Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vertex Pharmaceuticals Patents
Vertex Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250057880-A1 | Cell therapy for diabetes | Pending | 28-Jul-2023 | ||
| US-20250025210-A1 | Macroencapsulation device implantation and transport system and methods | Pending | 21-Jul-2023 | ||
| US-20240158404-A1 | Modulators of alpha-1 antitrypsin | Pending | 09-Sep-2022 | ||
| AU-2023338957-A1 | Modulators of alpha-1 antitrypsin | Pending | 09-Sep-2022 | ||
| AU-2023320558-A1 | Compositions for the treatment of cftr-mediated diseases | Pending | 04-Aug-2022 | A61K31/4439 |
Vertex Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vertex Pharmaceuticals Investments & Acquisitions (21)
Vertex Pharmaceuticals’s most recent deal was a Later Stage VC with Arbor Biotechnologies for . The deal was made on 18-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Arbor Biotechnologies | 18-Mar-2025 | Later Stage VC | Biotechnology | ||
| Septerna (Novel G Protein-Coupled Receptor Program) | 12-Sep-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Alpine Immune Sciences | 20-Apr-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Entrada Therapeutics | 08-Feb-2023 | PIPE | Drug Delivery | ||
| ViaCyte | 27-Sep-2022 | Merger/Acquisition | Drug Discovery |
Vertex Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated August, 29, 2024
19.56 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Vertex Pharmaceuticals Exits (5)
Vertex Pharmaceuticals’s most recent exit was on 11-Mar-2020 from Kymera Therapeutics. The exit was categorized as with 12 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kymera Therapeutics | 11-Mar-2020 | Completed |
|
||
| Kymera Therapeutics | 15-May-2019 | Completed |
|
||
| Moderna | 07-Sep-2016 | Completed |
|
||
| CRISPR Therapeutics | 24-Jun-2016 | Completed |
|
||
| Altus Pharmaceuticals | 06-Mar-2007 | PIPE | Completed |
|
Vertex Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Vertex Pharmaceuticals (canada) Incorporated | Toronto, Canada | 2003 |
Vertex Pharmaceuticals FAQs
-
When was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989.
-
Where is Vertex Pharmaceuticals headquartered?
Vertex Pharmaceuticals is headquartered in Boston, MA.
-
What is the size of Vertex Pharmaceuticals?
Vertex Pharmaceuticals has 6,100 total employees.
-
What industry is Vertex Pharmaceuticals in?
Vertex Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Vertex Pharmaceuticals a private or public company?
Vertex Pharmaceuticals is a Public company.
-
What is Vertex Pharmaceuticals’s stock symbol?
The ticker symbol for Vertex Pharmaceuticals is VRTX.
-
What is the current stock price of Vertex Pharmaceuticals?
As of 17-Apr-2025 the stock price of Vertex Pharmaceuticals is $489.10.
-
What is the current market cap of Vertex Pharmaceuticals?
The current market capitalization of Vertex Pharmaceuticals is $126B.
-
What is Vertex Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Vertex Pharmaceuticals is $11B.
-
Who are Vertex Pharmaceuticals’s competitors?
Regeneron Pharmaceuticals, Bluebird Bio, Ionis Pharmaceuticals, Altimmune, and Minerva Neurosciences are some of the 45 competitors of Vertex Pharmaceuticals.
-
What is Vertex Pharmaceuticals’s annual earnings per share (EPS)?
Vertex Pharmaceuticals’s EPS for 12 months was -$2.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
